Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome ,
, Medicine (Baltimore), vol.53, pp.343-64, 1974.
Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis, Arthritis Care Res, vol.68, issue.9, pp.1320-1351, 2016. ,
Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis, Ann Rheum Dis, vol.52, issue.3, pp.174-180, 1993. ,
Mortality in spondylarthritis. Jt Bone Spine Rev Rhum, vol.78, pp.466-70, 2011. ,
Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis ,
, Rheumatol Int, vol.33, issue.9, pp.2199-213, 2013.
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Ann Rheum Dis, vol.64, issue.8, pp.1150-1157, 2005. ,
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-? therapy and other novel approaches, Arthritis Res, vol.4, issue.5, pp.307-328, 2002. ,
New treatment targets for axial spondyloarthritis, Rheumatol Oxf Engl, 2016. ,
Are we ready for therapeutic drug monitoring of biologic therapeutics?, Arthritis Res Ther, vol.13, issue.4, p.120, 2011. ,
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis, J Clin Pharmacol, 2008. ,
Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients, Open Rheumatol J, vol.11, pp.75-87, 2017. ,
, Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation, Ann Rheum Dis, vol.66, issue.1, pp.133-137, 2007.
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Ann Rheum Dis, vol.66, issue.9, pp.1252-1256, 2007. ,
, Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases, Arthritis Res Ther, 2011.
, Jun, vol.27, issue.3, p.105
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases, Clin Pharmacol Adv Appl, vol.9, pp.101-112, 2017.,
URL : https://hal.archives-ouvertes.fr/hal-01980768
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis, 2013. ,
Anti-TNF-? biotherapies: perspectives for evidence-based personalized medicine, Immunotherapy, vol.4, issue.11, pp.1167-79, 2012. ,
ANNALS EXPRESS: Therapeutic drug monitoring of TNF inhibitors in the management of chronic inflammatory diseases, Ann Clin Biochem, 2018. ,
A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies, Ann Rheum Dis, 2014. ,
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis, Ther Drug Monit, vol.39, issue.4, pp.360-363, 2017.,
URL : https://hal.archives-ouvertes.fr/hal-01980745
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis, vol.70, issue.1, pp.25-31, 2011. ,
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal, Ann Rheum Dis, vol.68, issue.6, pp.770-776, 2009. ,
, Classification criteria for psoriatic arthritis: development of new criteria from a large international study, Arthritis Rheum, vol.54, issue.8, pp.2665-73, 2006.
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol, vol.21, issue.12, 1994. ,
REFERENCES REFERENCES and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study, Clin Chem Lab Med, vol.54, issue.7, pp.346-54, 2016. ,
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study, Arthritis Res Ther, vol.18, p.25, 2016. ,
, Rev Med Interne, vol.37, issue.5, pp.343-352, 2016.
, Prevalence of TNF-? blocker immunogenicity in psoriatic arthritis, J Rheumatol, 2015.
Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up, Ann Rheum Dis, vol.74, issue.2, pp.396-401, 2015. ,
Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation, Arthritis Res Ther, vol.16, issue.4, p.160, 2014. ,
Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity, J Rheumatol, 2015. ,